Development of Intratumoral Drug Delivery Based Strategies for Antitumor Therapy
DOI: https://doi.org/10.2147/dddt.s467835
IF: 4.3188
2024-06-12
Drug Design Development and Therapy
Abstract:Zhimei Jiang, 1– 3 Yuzhi Fu, 1– 3 Hongxin Shen 1– 3 1 Department of Pharmacy, West China Second University Hospital of Sichuan University, Chengdu, People's Republic of China; 2 Evidence-Based Pharmacy Center, West China Second University Hospital of Sichuan University, Chengdu, People's Republic of China; 3 Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, People's Republic of China Correspondence: Hongxin Shen, West China Second University Hospital, Sichuan University, No. 20, Third Section, Renmin South Road, Chengdu, Sichuan, 610041, People's Republic of China, Email Research for tumor treatment with significant therapy effects and minimal side-effects has been widely carried over the past few decades. Different drug forms have received a lot of attention. However, systemic biodistribution induces efficacy and safety issues. Intratumoral delivery of agents might overcome these problems because of its abundant tumor accumulation and retention, thereby reducing side effects. Delivering hydrogels, nanoparticles, microneedles, and microspheres drug carriers directly to tumors can realize not only targeted tumor therapy but also low side-effects. Furthermore, intratumoral administration has been integrated with treatment strategies such as chemotherapy, enhancing radiotherapy, immunotherapy, phototherapy, magnetic fluid hyperthermia, and multimodal therapy. Some of these strategies are ongoing clinical trials or applied clinically. However, many barriers hinder it from being an ideal and widely used option, such as decreased drug penetration impeded by collagen fibers of a tumor, drug squeezed out by high density and high pressure, mature intratumoral injection technique. In this review, we systematically discuss intratumoral delivery of different drug carriers and current development of intratumoral therapy strategies. Keywords: intratumoral drug delivery, drug carrier, treatment strategy, antitumor therapy Graphical At present, many kinds of strategies have been developed for the therapy of various tumors, such as surgery, chemotherapy, radiotherapy, immunotherapy, and photothermal therapy. Some early solid tumors are preferentially treated by surgical resection; however, advanced carcinomas at stage III–IV, inoperable regions, or elderly patients unable to undergo surgical treatment require improved systemic treatment strategies. 1 Currently, there are still many challenges in cancer treatment. Traditional treatment methods such as radiation therapy and chemotherapy can inhibit tumor growth to a certain extent but are unlikely to completely kill tumor cells, resulting in significant side-effects, tumor recurrence, and metastasis. Therapeutic drug delivery systems have been widely investigated because of their anticancer potential to target tumors, enhance radiotherapy, or immunotherapy. However, challenges and limitations also urgently need to be solved. Drugs show the characteristics of non-specific delivery, causing various adverse reactions and inefficient treatment. Hopefully, the intratumoral delivery system which refers to drugs directly injected into tumors may provide a meaningful response. Its unique anticancer efficacy was associated with increased tumor distribution, prolonged retention of therapeutic drugs within the tumors, and decreased normal tissue uptake. 2,3 Intratumoral therapy is different from systemic administration, because it directly delivers therapeutic substances into the tumor sites, increases the concentration and station of antitumor drugs, thereby enhancing the antitumor effect and reducing systemic toxicity. 4 Recently, intratumoral delivery systems have been extensively explored. This mainly focused on nanoparticles, 5 hydrogels, 6 microneedles, 7 microspheres, 8 etc. For example, Chattopadhyay et al 3,9 employed the intratumoral injection of trastuzumab-gold nanoparticles to maximize tumor localization for X-ray radio sensitization and reduce uptake by the liver and spleen. It caused 25-fold higher tumor uptake, 10-fold lower spleen uptake of trastuzumab-gold nanoparticles than that post-intravenous injection at 48 hours. Its liver uptake was also modestly decreased. In addition, the pharmacodynamics revealed that tumor size was decreased by 2-fold in a trastuzumab-gold nanoparticles and X-radiation group that in an X-radiation alone group. However, for intratumoral drug delivery systems, the complex and chaotic vasculatures formed in and around the tumor, and the properties of their abnormal mesenchyme, 10 hindered effective permeation of therapeutic drugs to tumor cells which reduced their anticancer activity. 11< -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal